Literature DB >> 16969645

Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort.

P André1, B Balkau, C Born, M A Charles, E Eschwège.   

Abstract

AIMS/HYPOTHESIS: Among hepatic markers, gamma-glutamyltransferase (GGT) is the main predictor for development of type 2 diabetes, but there are no data to date on changes in GGT and type 2 diabetes incidence.
METHODS: Data at baseline and at 3 years from the D.E.S.I.R. cohort were used, comprising 2,071 men and 2,130 women without baseline diabetes.
RESULTS: Changes in GGT level were correlated with changes in markers of insulin resistance (fasting insulin, homeostasis model assessment of insulin resistance), as well as with the following elements of the metabolic syndrome: central obesity, and increased fasting glucose, triglycerides and blood pressure (systolic and diastolic). The 3-year increase in GGT was associated with incident type 2 diabetes in both sexes, after adjusting for age and baseline GGT. After further adjustment for baseline confounding factors, including alanine-aminotransferase, alcohol intake, obesity and fasting insulin, the odds ratios (95% CI) for an association between incident type 2 diabetes and unchanged or increased (as opposed to decreased) GGT levels were 2.54 (1.38-4.68) in men (p=0.003) and 2.78 (1.20-6.42) in women (p=0.02). These associations were slightly attenuated after adjusting for the 3-year change in BMI, alcohol consumption and fasting insulin, the odds ratios being 2.49 (1.28-4.86) in men and 2.53 (1.01-6.40) in women. This relationship was not dependent on intra-individual variability. CONCLUSIONS/
INTERPRETATION: An unchanged or increased GGT level over time, even when GGT is in the normal range, is correlated with increasing insulin resistance and is associated with a risk of incident type 2 diabetes in both sexes, independently of baseline GGT, which is itself a diabetes risk factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969645      PMCID: PMC1975686          DOI: 10.1007/s00125-006-0418-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.

Authors:  I J Perry; S G Wannamethee; A G Shaper
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

Review 3.  Intra- and inter-individual biological variability data bank.

Authors:  M A Sebastián-Gámbaro; F J Lirón-Hernández; X Fuentes-Arderiu
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-11

4.  Gamma-glutamyltransferase and diabetes--a 4 year follow-up study.

Authors:  D-H Lee; M-H Ha; J-H Kim; D C Christiani; M D Gross; M Steffes; R Blomhoff; D R Jacobs
Journal:  Diabetologia       Date:  2003-03-01       Impact factor: 10.122

5.  Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

Authors:  Naveed Sattar; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Adrian Stanley; Ewan Forrest; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

6.  Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome).

Authors:  P André; B Balkau; C Born; B Royer; E Wilpart; M A Charles; E Eschwège
Journal:  Diabetes Metab       Date:  2005-12       Impact factor: 6.041

7.  Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men.

Authors:  N Nakanishi; K Nishina; W Li; M Sato; K Suzuki; K Tatara
Journal:  J Intern Med       Date:  2003-09       Impact factor: 8.989

8.  Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Duk-Hee Lee; David R Jacobs; Myron Gross; Catarina I Kiefe; Jeffrey Roseman; Cora E Lewis; Michael Steffes
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

9.  Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromsø Study.

Authors:  O Nilssen; O H Førde
Journal:  Am J Epidemiol       Date:  1994-04-15       Impact factor: 4.897

10.  Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.

Authors:  Noriyuki Nakanishi; Kenji Suzuki; Kozo Tatara
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

  10 in total
  32 in total

Review 1.  From bed to bench: which attitude towards the laboratory liver tests should health care practitioners strike?

Authors:  Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

2.  Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects.

Authors:  Zheng Chen; Cheng-Kun Han; Ling-Ling Pan; Hui-Jie Zhang; Zhi-Min Ma; Zhu-Feng Huang; Shi Chen; Xiong-Jie Zhuang; Zhi-Bin Li; Xiao-Ying Li; Xue-Jun Li; Shu-Yu Yang
Journal:  Dig Dis Sci       Date:  2014-05-27       Impact factor: 3.199

3.  New evidence for an association between liver enzymes and pancreatic islet β-cell dysfunction in young obese patients.

Authors:  Li Wang; Juanjuan Zhang; Bokai Wang; Yuwen Zhang; Jie Hong; Yifei Zhang; Weiqing Wang; Weiqiong Gu
Journal:  Endocrine       Date:  2013-04-03       Impact factor: 3.633

4.  High prevalence of prediabetes and diabetes in a population exposed to high levels of an organochlorine cocktail.

Authors:  J Ukropec; Z Radikova; M Huckova; J Koska; A Kocan; E Sebokova; B Drobna; T Trnovec; K Susienkova; V Labudova; D Gasperikova; P Langer; I Klimes
Journal:  Diabetologia       Date:  2010-02-25       Impact factor: 10.122

5.  C-reactive protein and gamma-glutamyltransferase concentrations in relation to the prevalence of type 2 diabetes diagnosed by glucose or HbA1c criteria in Chinese adults in Qingdao, China.

Authors:  J Ren; Z C Pang; W G Gao; H R Nan; S J Wang; L Zhang; Q Qiao
Journal:  Exp Diabetes Res       Date:  2010-11-07

6.  Risk factors for incident type 2 diabetes in individuals with a BMI of <27 kg/m2: the role of gamma-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR).

Authors:  A Gautier; B Balkau; C Lange; J Tichet; F Bonnet
Journal:  Diabetologia       Date:  2009-11-20       Impact factor: 10.122

7.  Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults.

Authors:  Alexander M Strasak; Cecily C Kelleher; Jochen Klenk; Larry J Brant; Elfriede Ruttmann; Kilian Rapp; Hans Concin; Günter Diem; Karl P Pfeiffer; Hanno Ulmer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

8.  Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis.

Authors:  C C Lee; A I Adler; M S Sandhu; S J Sharp; N G Forouhi; S Erqou; R Luben; S Bingham; K T Khaw; N J Wareham
Journal:  Diabetologia       Date:  2009-03-27       Impact factor: 10.122

9.  Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.

Authors:  Xiaowen Liu; Ole-Petter R Hamnvik; John P Chamberland; Michael Petrou; Huizhi Gong; Costas A Christophi; David C Christiani; Stefanos N Kales; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-03-15       Impact factor: 8.694

10.  Association of cardiorespiratory fitness with elevated hepatic enzyme and liver fat in Japanese patients with impaired glucose tolerance and type 2 diabetes mellitus.

Authors:  Mayumi Nagano; Haruka Sasaki; Shuzo Kumagai
Journal:  J Sports Sci Med       Date:  2010-09-01       Impact factor: 2.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.